Oscar Health Inc vs Trip.com Group Ltd — how do they compare? Oscar Health Inc trades at $33.15 (market cap $10.22B), while Trip.com Group Ltd trades at $38.66 (market cap $23.75B). The key difference: Trip.com Group Ltd is far larger — about 2.3× Oscar Health Inc's market cap, and Trip.com Group Ltd pays a 0.42% dividend while Oscar Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oscar Health Inc for 15 Days and Trip.com Group Ltd for 79 Days on average.
| OSCR | TCOM | |
|---|---|---|
Market Cap | $10.22B | $23.75B |
Volume | 4,123,394 | 2,089,737 |
Sector | Health | Consumer Cyclical |
52-Week High | $33.81 | $78.96 |
52-Week Low | $10.85 | $37.96 |
Typical Hold Time | 15 Days | 79 Days |
Enterprise Value | $6.57B | $15.91B |
Dividend Yield | — | 0.42% |
Signals from Pluang's Aura AI — not financial advice
OSCR trades at $32.91, up 1.76% today, with a bullish technical outlook from moving averages and mixed oscillators. The stock shows strong revenue growth, with 2026 revenue projected at $15.3B, and profitability turning positive with a net income margin of 3.59%. Recent news highlights market share gains in the ACA sector and raised 2026 guidance, though Q3 2026 EPS is yet to be reported.
The outlook is positive with analyst consensus at Buy and a $34 price target, but risks include rising medical costs and execution challenges. Upside potential exists from scalable growth and margin expansion, yet volatility near resistance levels and competitive pressures warrant caution for investors.
Trip.com Group (TCOM) trades at $38.09, down 0.44% on the day, with technical indicators showing bearish momentum despite oversold RSI readings. The company demonstrates strong fundamentals with revenue growth from $53.3B in 2024 to $62.4B in 2025 and robust net income margins of 36.9%. Recent Q2 2026 earnings beat expectations with $1.07 EPS versus $0.98 expected, though regulatory headwinds from Chinese antitrust actions create uncertainty.
The investment outlook remains positive given attractive valuations (P/E 7.36, EV/EBITDA 3.55) and analyst consensus price target of $56.64 representing 49% upside. However, regulatory risks and competitive pressures from dismantled ranking algorithms require monitoring. With 70% analyst buy ratings and strong cash flow generation, TCOM offers value for patient investors despite near-term technical weakness.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →